SUBLOCADE carries the whole story now
- SUBLOCADE made up 73% of Q1 2026 global net revenue, so one product now drives the stock.
- U.S. SUBLOCADE revenue rose 33% year over year in Q1, helped by 20% dispense unit growth and price mix.
- Management said the Q1 volume comparison was easy and still expects mid-teens dispense unit growth for the full year.
- The two key pipeline assets, INDV-2000 and INDV-6001, are no longer moving forward internally.
- The next big question is whether Indivior can buy new growth without taking on too much debt.
A strong core, a thin future
Indivior has become a focused bet on SUBLOCADE. That is good when the product is growing fast. In Q1 2026, U.S. SUBLOCADE net revenue rose 33% from a year earlier, and the product reached 73% of company net revenue.
The bull case is simple. If SUBLOCADE keeps gaining patients, it can offset the decline of older SUBOXONE products and may let total revenue grow in 2026. Restructuring and lower research spending could also help profits if sales keep beating expectations.
The bear case is also simple. Indivior no longer has a strong late-stage internal pipeline after INDV-2000 missed its main Phase 2 goal and INDV-6001 was not moved into Phase 3 by the company. Long-term growth now depends on SUBLOCADE staying strong or on business development. Management is looking for commercial-stage assets with more than $200M of peak sales potential and has said leverage could go up to 3x for the right deal.
Paid by health systems and insurers
Indivior makes money by selling prescription medicines, mainly in the U.S. Its main customers are not individual patients paying cash. Revenue comes through government payors, commercial insurers, pharmacies, clinics, hospitals, and organized health systems.
SUBLOCADE is a once-monthly injection of buprenorphine for opioid use disorder. Long-acting injections can help because patients do not need to take a daily dose. The harder part is access. Indivior must get the drug covered, supplied, and used across health systems and criminal justice programs.
The model breaks if SUBLOCADE volume slows, if rebates and discounts rise, or if older SUBOXONE revenue falls faster than the core product grows. A $14M Q1 gross-to-net benefit is also an open question because it may reverse as a headwind in later quarters.
One product leads the pack
SUBLOCADE
This monthly buprenorphine injection is Indivior's main product. It was 73% of Q1 2026 global net revenue and is the key driver to watch.
SUBOXONE Film
This under-the-tongue film combines buprenorphine and naloxone. It is a legacy product and faces heavy generic competition in the U.S.
SUBOXONE and SUBUTEX Tablets
These older oral products are sold mainly outside the U.S. Their sales are under pressure from generic erosion.
OPVEE
OPVEE is a nalmefene nasal spray for opioid overdose. Indivior stopped sales and marketing support, so revenue is expected to be negligible.
PERSERIS
PERSERIS is a long-acting injectable for schizophrenia. Promotion stopped in July 2024, and revenue is expected to be negligible.
INDV-2000 and INDV-6001
These were the key pipeline assets, but both failed to remain internal growth drivers. INDV-2000 did not meet its main Phase 2 goal, and Indivior will not pursue Phase 3 for INDV-6001.
Revenue is tightly concentrated
The product mix is from Q1 2026 global net revenue. Indivior reports one operating segment, but the real investor issue is product concentration, with SUBLOCADE at 73% of revenue.
What could go wrong
SUBLOCADE growth slows
High impact · Medium oddsSUBLOCADE is now 73% of Q1 2026 net revenue. If volume slows, price mix worsens, or payors demand bigger discounts, the whole company feels it. Management said Q1 had an easy comparison and expects mid-teens dispense unit growth for the full year, not 20%.
No late-stage pipeline
High impact · High oddsINDV-2000 and INDV-6001 no longer support the internal long-term growth story. That makes Indivior more dependent on buying or licensing assets. A poor deal could fail to add growth and still add debt.
Legacy products keep eroding
Medium impact · High oddsSUBOXONE Film and older tablets face generic competition. These products still matter because the sublingual and other group was 25% of Q1 2026 global net revenue. If they fall faster than SUBLOCADE grows, total revenue can still decline.
SUBOXONE dental litigation
High impact · Medium oddsIndivior faces lawsuits alleging SUBOXONE Film caused dental injuries and that warnings were not adequate. The size of the possible cash cost is still an open question. Current accruals may need to change if case facts or settlement talks move against the company.
Healthcare system disruption
Medium impact · Medium oddsIndivior depends on payers, providers, distributors, and other third parties to get controlled medicines to patients. The company said a February 2024 breach at a revenue and payment cycle management provider disrupted the healthcare system and affected SUBLOCADE revenue in the first and second quarters of 2024. Similar problems could interrupt access again.
In one breath
What does Indivior do?
Indivior develops and sells medicines for substance use disorders, especially opioid use disorder. Its most important product is SUBLOCADE, a monthly injection of buprenorphine.
Why is SUBLOCADE so important to INDV stock?
SUBLOCADE was 73% of Q1 2026 global net revenue. That means the stock now depends heavily on whether this one drug can keep growing.
Does Indivior have a strong pipeline?
Not right now. INDV-2000 did not meet its main Phase 2 goal, and Indivior will not take INDV-6001 into Phase 3, so future growth may need to come from deals.
What should investors watch next?
Watch U.S. SUBLOCADE growth each quarter, any business development deal, and the SUBOXONE dental litigation. Those items will likely shape the next year of the story.